COMP <GO>
CORT vs ARWR // EV/EBITDA & P/E VALUATION
Corcept Therapeutics Incorporated (NASDAQ) VS. Arrowhead Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: CORT 3
— ARWR 8
▲ EV/EBITDA & P/E VALUATION LEADER: ARWR
LAST: $80.46 (-0.81%) • MKT CAP: $8.77B
valuation
95.0x
LAST: $59.57 (-0.55%) • MKT CAP: $8.46B
valuation
73.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CORT VS. ARWR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CORT | ARWR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.80% | 11.10% | -6.30 | ARWR | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 95.0x | 73.8x | +21.20 | ARWR | /valuation <GO> |
| Free Cash Flow Yield | 1.53% | 1.84% | -0.31 | ARWR | /fcf-yield <GO> |
| Operating Margin | 5.90% | 11.90% | -6.00 | ARWR | /operating-margins <GO> |
| Net Profit Margin | 13.10% | -0.20% | +13.30 | CORT | /net-margins <GO> |
| Revenue Growth (YoY) | 12.80% | 180.00% | -167.20 | ARWR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 6.60 | +19.40 | CORT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.6 | 41.3 | -13.70 | ARWR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.96 | -0.08 | ARWR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 78.3x | 18.0x | +60.30 | ARWR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.77B | $8.46B | $307.8M | CORT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CORT REV | ARWR REV | CORT GROSS % | ARWR GROSS % | CORT FCF | ARWR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $761.4M | $829.4M | 98.3% | — | $141.8M | $156.9M |
| FY 2024 | $675.0M | $3.6M | 98.4% | — | $196.1M | -$604.3M |
| FY 2023 | $482.4M | $240.7M | — | — | $105.0M | -$164.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CORT // BETA 0.88
ARWR // BETA 0.96